Milademetan (RAIN-32), an MDM2-p53 antagonist, has been assessed in solid tumors, including CCA, with phase I trials showing manageable safety profiles and modest antitumor activity [65]. This evidence concerns the gene TP53 and cholangiocarcinoma.